Gameto

Gameto’s VP of Manufacturing and Therapeutic Development, Bruna Paulsen, PhD, will be presenting at the 4th annual iPSC Drug Development and Manufacturing Summit in Boston, Massachusetts this week. Bruna’s talk, “hiPSC-derived ovarian support cells as a novel infertility treatment,” will be focused on Gameto’s manufacturing processes, namely how we use a female iPSC line to derive our product candidate Fertilo, ovarian support cells (OSCs) for use in in vitro maturation processes. Her talk will be located at The Colonnade on Thursday, October 3rd from 12:30 to 1pm ET. We would love to see you there!

We are pleased to welcome Dr. Jaime Knopman as Chairwoman of Gameto’s Clinical Advisory Board! Dr. Knopman, a board-certified reproductive endocrinologist, brings extensive experience in fertility treatments, IVF, and egg freezing. She currently serves as the Director of Fertility Preservation for CCRM Fertility of New York and is the Chief Medical Officer of The Chick Mission, a nonprofit dedicated to helping young cancer patients navigate fertility challenges. Dr. Knopman’s expertise and leadership will play a pivotal role as we continue advancing our programs, including our lead program Fertilo, our novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) that is designed to improve IVF and egg freezing processes by reducing hormonal stimulation and maturing eggs outside the body. Welcome, Jaime! We’re excited to have you on board and look forward to the impact we’ll make together! Click here for more info: https://lnkd.in/eCwXb8BH

Check out these highlights from the fertility preservation event that we held earlier this week. Thank you to our speakers and everyone who attended for a wonderful evening! Jaime Knopman Dina Radenkovic (Turner) Natalie Lampert The Chick Mission RESOLVE: The National Infertility Association CCRM Fertility Camila Caso Izzi Wayner Risa Levine Bruna Paulsen, PhD Agustina Figueroa Imfeld Emily Bosworth Kylie Jordan

Yesterday, Gameto’s Director of IR, Kylie Jordan attended the Wyss Institute at Harvard University first annual Women's Health Catalyst Symposium in Boston. The event was held in collaboration with Advanced Research Projects Agency for Health (ARPA-H), Women's Health Access Matters (WHAM), and FemTechnology Summit and highlighted the research and technology translation across the Institute’s vast community of innovators. Gameto partnered with the Wyss via a sponsored research agreement to create human ovarian organoids in a dish that could be used to develop new treatments for women’s reproductive health. We are grateful for the Wyss Institute’s continued support as we work to bring our innovative solutions to patients.

What a wonderful evening talking about one of our favorite topics, egg freezing! Yesterday evening, Gameto hosted a discussion surrounding the present state of fertility preservation technology and where the field is moving. We heard from our Co-founder and CEO, Dina Radenkovic (Turner), who presented on our lead program, Fertilo, a cell-based solution aimed at improving IVF and egg freezing processes by maturing eggs outside the body. Jaime Knopman, a reproductive endocrinologist and Director of Fertility Preservation at CCRM and Chief Medical Officer at The Chick Mission talked about how egg freezing is rapidly growing and starting to change the game for women everywhere. The evening concluded with an interesting panel discussion between Dina, Jaime and author/journalist Natalie Lampert. Natalie recently published her first book, The Big Freeze, that documents her personal journey contemplating her own fertility preservation. Their conversation was informative and thought-provoking and sparked a lively audience Q&A session to wrap up the night. Thank you to everyone who attended for a wonderful evening and to our panelists for a great discussion!

Great conversation this morning at the NYSE between Gameto’s Co-Founder and CEO Dina Radenkovic (Turner) and BiotechTV’s Ali Gorman. Thank you to our hosts Brad Loncar, Ali Gorman, and Johanna (Rodriguez) Grossman, PhD! Check out the full interview below.

🚨 Exciting News at Gameto! 🚨 Dr. Ghassan Haddad has joined the Gameto team as our new Chief Medical Officer (CMO). Dr. Haddad will help lead the clinical development of Fertilo, our novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) that is designed to improve IVF and egg freezing processes by reducing hormonal stimulation and maturing eggs outside the body, as we work hard to meet the requirements to initiate Fertilo’s Phase 3 clinical trial. Dr. Haddad’s experiences and both an accomplished physician and entrepreneur will bring valuable insights to the Gameto team at this pivotal time. "We are excited to welcome Dr. Haddad to Gameto, particularly at this pivotal time as we are preparing to meet requirements to initiate Fertilo’s Phase 3 clinical trial,” said Dr. Dina Radenkovic, Gameto’s Co-founder and CEO. “Dr. Haddad’s range of experiences as both a practicing reproductive medicine physician and successful entrepreneur make him a valuable addition to the Gameto team.” Check out the full press release here: https://lnkd.in/evZzy3JB

Last chance to vote for our #SXSW panel submission, ‘Transforming Women's Health: From Pain to Progress.’ If you haven’t voted already, please do so at the link below so that we can have this important conversation on the #SXSW stage. Thank you for voting! https://lnkd.in/eTjNbQ6B Dina Radenkovic Maneesh Jain Olivia Sterns Walton Chelsea M.R. Hirschhorn Mirvie Ingeborg Investments Frida

Compelling story about our investor Deena Shakir from Lux Capital and how her experience with postpartum preeclampsia reinforced why she invests in women’s, maternal, and infant health companies like Gameto, Maven Clinic, Alife, and Summer Health. This story sounds way too familiar for so many, even for women who are leaders in the women’s health and biotech spaces. Our CEO and Co-founder Dina Radenkovic was motivated to start Gameto when thinking about her own egg freezing and noticed the lack of innovative solutions in women’s health that prioritize the female patient experience. At Gameto, she helped develop our lead product candidate Fertilo, induced pluripotent stem cell (iPSC)-derived ovarian support cells that mature eggs outside of the body, with the goal of making IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections. Dina was a patient herself in our egg freezing trial, and later on, when giving birth to her first child, Dina’s own uterus was saved by the invention of another women’s health startup, Alydia Health, which was acquired by Organon. We all have skin in the game, and need to continue building and investing in better solutions that prioritize women. Thank you to Deena for sharing your story!

We are excited to share a new publication discussing the focus of our program Fertilo, a cell-based approach to IVM that is made of induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) that mature the eggs outside of the body. Gameto CSO Christian Kramme, PhD and our Clinical Advisor, Pietro Bortoletto, recently collaborated on a paper as part of the European Society of Human Reproduction and Embryology (ESHRE) Journal Club. The ESHRE Journal Club discussion focused on a study by Mostinckx et al. (2024), that reported on experiences with IVM in expected hyper-responders, compared with traditional ovarian stimulation for ICSI. The discussion expanded to possible benefits and limits of IVM, obstacles to overcome for its application in clinical practice and future perspectives. The paper discusses the evolution of IVM from its early challenges to its current potential as a safer, cost-effective alternative to conventional ovarian stimulation in IVF. It highlights the biological rationale, barriers to adoption, and the latest advancements that could enhance IVM's efficacy in clinical practice. Key Takeaways: ➡ IVM offers a safer, less hormone-intensive option for patients, particularly hyper-responders, by reducing the risk of ovarian hyperstimulation syndrome (OHSS). ➡ Recent advancements like CAPA-IVM and OSC-IVM (Fertilo product candidate) improve oocyte maturation and embryo development, making IVM more competitive with traditional IVF. ➡ Widespread adoption of IVM is hindered by technical challenges, varying protocols, and the need for standardized guidelines and training for clinicians and embryologists. We are excited to continue working with this amazing group of researchers and more to continue driving innovation in the IVM field as a treatment option for patients seeking fertility & fertility preservation treatments. Sofia Makieva PhD, Juan J. Fraire-Zamora, Omar Ammar, Georgios Liperis, PhD, Flor Sánchez, PhD, Robert Gilchrist, Claudia Massarotti, Boston IVF, UNSW Link to the full publication here: https://lnkd.in/d_p_jcS5